**Chapter 4**

*Multiple Myeloma*

methodologies: a clinical point of view.

2020;34(4):985-1005. doi: https://doi. org/10.1038/s41375-020-0734-z.

Sentman CL. Bispecific T-cell engagers

[75] Huehls AM, Coupet TA,

for cancer immunotherapy. Immunology and cell biology. 2015;93(3):290-6. doi: https://doi.

org/10.1038/icb.2014.93.

therapeutics. 2014;27(2):129-38. doi:

[69] Domingo E, Schwartz Jr S. BRAF (v-raf murine sarcoma viral oncogene homolog B1. Atlas of Genetics and Cytogenetics in Oncology and

[70] Lee S-T, Kim SW, Ki C-S, Jang J-H,

implication of highly sensitive detection of the BRAF V600E mutation in fineneedle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. The Journal of Clinical Endocrinology & Metabolism. 2012;97(7):2299-306.

Shin JH, Oh YL, et al. Clinical

doi: https://doi.org/10.1210/

[71] Baik CS, Myall NJ, Wakelee HA. Targeting BRAF-mutant non-small cell lung cancer: From molecular profiling to

rationally designed therapy. The oncologist. 2017;22(7):786. doi: 10.1634/

[72] van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal

[73] Cavo M. Facing lenalidomiderefractory myeloma. Blood, The Journal of the American Society of Hematology. 2019;134(2):99-101. doi:

[74] Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic

antibodies targeting CD 38 in hematological malignancies and beyond. Immunological reviews. 2016;270(1):95-112. doi: https://doi.

org/10.1111/imr.12389.

https://doi.org/10.1182/ blood-2019-04-901157.

approaches. Leukemia.

theoncologist.2016-0458.

jc.2011-3135.

Pulmonary pharmacology &

https://doi.org/10.1016/j. pupt.2014.01.005.

Haematology. 2004.

**44**
